GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » Beta

Wuhan YZY Biopharma Co (HKSE:02496) Beta : N/A (As of Jun. 05, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-05), Wuhan YZY Biopharma Co's Beta is Not available.


Wuhan YZY Biopharma Co Beta Historical Data

The historical data trend for Wuhan YZY Biopharma Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan YZY Biopharma Co Beta Chart

Wuhan YZY Biopharma Co Annual Data
Trend Dec21 Dec22 Dec23
Beta
- - -

Wuhan YZY Biopharma Co Semi-Annual Data
Dec21 Dec22 Dec23
Beta - - -

Competitive Comparison of Wuhan YZY Biopharma Co's Beta

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan YZY Biopharma Co's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Beta distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's Beta falls into.



Wuhan YZY Biopharma Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Wuhan YZY Biopharma Co  (HKSE:02496) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Wuhan YZY Biopharma Co Beta Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan YZY Biopharma Co (HKSE:02496) Business Description

Traded in Other Exchanges
N/A
Address
No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing new class of innovative medicines in respect to anti-tumor bispecific antibody.
Executives
Dragon Merit Holdings Limited 2201 Interest of corporation controlled by you
Robust Sun Holdings Limited 2201 Interest of corporation controlled by you
Cspc Pharmaceutical Group Limited 2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si 2101 Beneficial owner
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Hong Wei
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng
Tong De Qian Yuan Bei Jing Tou Zi Guan Li You Xian Gong Si
Wang Hongjie 2201 Interest of corporation controlled by you
Wu Shangzhi 2201 Interest of corporation controlled by you

Wuhan YZY Biopharma Co (HKSE:02496) Headlines

No Headlines